Skip to content

Do financial incentives improve the treatment of diabetes in Swiss primary care?

Impact of financial incentives to improve quality indicators in diabetes patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN13305645
Enrollment
70
Registered
2018-03-20
Start date
2018-05-15
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus Nutritional, Metabolic, Endocrine Diabetes mellitus

Interventions

The level of randomization will be at the practice level. The participating practices will be divided into an intervention and control group. Randomization will be stratified by current performance st

Sponsors

Institute of Primary Care
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Up to December 2017, 290 GPs from 14 German speaking cantons of Switzerland participated in the FIRE project. In December 2017, the database contained data of 3,372,343 encounters of 345,811 patients. The FIRE database, consisting of administrative data, vital signs (blood pressure), lab values (Hba1c), diagnostic codes (ICPC-2), and medication data (ATC codes) provides the database for the project. Structural data on participating GP practices (physicians’ age and training, practice type (single-handed, double or group practice) and location, laboratory connection) are collected at individual FIRE project entry. PCPs are eligible for the current study based on the FIRE database, if the dataset of 2017 is complete and a minimum threshold of 0.1 is achieved for the process indicators HbA1c and blood pressure, to rule out technical problems. Of the eligible PCPs, primary care patients with diabetes mellitus will be identified from the FIRE database according to the following criteria: 1. Patient with ICPC-2 codes T89 (insulin dependent diabetes mellitus) and T90 (insulin independent diabetes mellitus) 2. Patients with antidiabetic medication (oral antidiabetics and/or insulin) according to the pharmaceutical cost group (PCG) (A10A/A10B)

Exclusion criteria

Exclusion criteria: Incomplete data set of 2017 and/or a minimum threshold of 0.1 is not achieved for the process indicators HbA1c and blood pressure

Design outcomes

Primary

MeasureTime frame
Obtained from the FIRE database at baseline, 12 and 24 months: 1. Proportion of diabetic patients with last blood pressure measurement < 140/85 mmHg (clinical QI) 2. Proportion of diabetic patients with at least one measurement of HbA1c in the preceding 12 months (process QI)

Secondary

MeasureTime frame
Obtained from the FIRE database at baseline, 12 and 24 months: 1. Proportion of diabetic patients with at least one blood pressure measurement in the preceding 12 months (process QI) 2. Proportion of diabetic patients with HbA1c levels < 7.5% (clinical QI) 3. Proportion of diabetic patients with at least one cholesterol measurement in the preceding 12 months (process QI) 4. Proportion of diabetic patients with total cholesterol < 5 mmol/l (clinical QI)

Countries

Switzerland

Contacts

Public ContactRahel Meier
rahel.meier@usz.ch+41 (0)44 255 98 55

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 24, 2026